Evidence map›Paper›PMID 34921182›Full record

ArticleScientific reports2021

Functional and structural analysis of non-synonymous single nucleotide polymorphisms (nsSNPs) in the MYB oncoproteins associated with human cancer.

Shu Wen Lim, Kennet JunKai Tan, Osman Mohd Azuraidi, Maran Sathiya, Ee Chen Lim, Kok Song Lai, Wai-Sum Yap, Nik Abd Rahman Nik Mohd Afizan

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 22 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Biochemistry and biophysics reports · 2025
    Article
  6. Comprehensive computational analysis of deleterious nsSNPs inMolecular biology research communications · 2025
    Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. In-Silico Analysis of Deleterious SNPs ofLife (Basel, Switzerland) · 2022
    Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Shu Wen LimFaculty of Applied Sciences, UCSI University, No. 1, Jalan Menara Gading UCSI Height, 56000, Cheras, Kuala Lumpur, Malaysia.
Kennet JunKai TanFaculty of Applied Sciences, UCSI University, No. 1, Jalan Menara Gading UCSI Height, 56000, Cheras, Kuala Lumpur, Malaysia.
Osman Mohd AzuraidiDepartment of Cell and Molecular Biology, Faculty of Biotechnology and Biomolecular Sciences, 43400, Serdang, Selangor, Malaysia.
Maran SathiyaSchool of Pharmacy, Monash University Malaysia, Jalan Lagoon Selatan, 47500, Bandar Sunway, Selangor, Malaysia.
Ee Chen LimFaculty of Applied Sciences, UCSI University, No. 1, Jalan Menara Gading UCSI Height, 56000, Cheras, Kuala Lumpur, Malaysia.
Kok Song LaiHealth Sciences Division, Abu Dhabi Women's College, Higher Colleges of Technology, 41012, Abu Dhabi, United Arab Emirates.
Wai-Sum YapFaculty of Applied Sciences, UCSI University, No. 1, Jalan Menara Gading UCSI Height, 56000, Cheras, Kuala Lumpur, Malaysia. wsyap@ucsiuniversity.edu.my.
Nik Abd Rahman Nik Mohd AfizanDepartment of Cell and Molecular Biology, Faculty of Biotechnology and Biomolecular Sciences, 43400, Serdang, Selangor, Malaysia. m.afizan@upm.edu.
UCSI University · MYHigher Colleges of Technology · AEMonash University Malaysia · MY

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MYB proteins are highly conserved DNA-binding domains (DBD) and mutations in MYB oncoproteins have been reported to cause aberrant and augmented cancer progression. Identification of MYB molecular biomarkers predictive of cancer progression can be used for improving cancer management. To address this, a biomarker discovery pipeline was employed in investigating deleterious non-synonymous single nucleotide polymorphisms (nsSNPs) in predicting damaging and potential alterations on the properties of proteins. The nsSNP of the MYB family; MYB, MYBL1, and MYBL2 was extracted from the NCBI database. Five in silico tools (PROVEAN, SIFT, PolyPhen-2, SNPs&GO and PhD-SNP) were utilized to investigate the outcomes of nsSNPs. A total of 45 nsSNPs were predicted as high-risk and damaging, and were subjected to PMut and I-Mutant 2.0 for protein stability analysis. This resulted in 32 nsSNPs with decreased stability with a DDG score lower than - 0.5, indicating damaging effect. G111S, N183S, G122S, and S178C located within the helix-turn-helix (HTH) domain were predicted to be conserved, further posttranslational modifications and 3-D protein analysis indicated these nsSNPs to shift DNA-binding specificity of the protein thus altering the protein function. Findings from this study would help in the field of pharmacogenomic and cancer therapy towards better intervention and management of cancer.

Indexed as

Models, MolecularNeoplasmsProto-Oncogene Proteins c-mybComputer SimulationHumansPolymorphism, Single NucleotideProtein ConformationProtein StabilityMYB protein, humanProto-Oncogene Proteins c-myb

Identifiers

PMID34921182
PMCPMC8683427
OpenAlexW4200430176

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.